ThromboGenics Completes Patient Enrolment Of Second Phase III Trial…
December 17th, 2009
Main Category: Eye Health / Blindness Also Included In: Pharma Industry / Biotech Industry ThromboGenics NV , a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating …
Original post by MediLexicon
(click on the author/publication link above to see full post)